Monitor Dr. Reddy's for updates on Qdenga launch timing and initial private-market uptake in India post-H1 2027. The partnership expands Dr. Reddy's vaccines portfolio but has no near-term revenue contribution.
Price Chart
Executive Summary
Dr. Reddy's has entered into an exclusive distribution and marketing agreement with Takeda for Qdenga, a dengue vaccine, in India's private market. The vaccine was approved by CDSCO in July 2026 and is anticipated to become available in the first half of 2027. No upfront consideration or milestone payments were disclosed, and commercial terms are confidential.
Key Facts
- Dr. Reddy's signed an exclusive distribution and marketing agreement with Takeda for Qdenga (dengue vaccine) in India's private market on September 18, 2026.
- Qdenga received CDSCO marketing authorization in July 2026 for individuals aged 4-60 years, making it India's first approved dengue vaccine.
- No upfront consideration or milestone payment under the agreement; other commercial terms are confidential.
- Vaccine anticipated to become available in India in the first half of 2027.
- Takeda retains commercialization rights in India's public market and responsibility for manufacturing and importation.
- Qdenga has been approved in 43 countries and over 32 million doses distributed worldwide since 2022.
Financial Impact
No upfront or milestone payments disclosed; commercial terms confidential. Revenue impact depends on private-market uptake in India starting H1 2027.
Risk Factors
- Launch delayed beyond H1 2027 due to regulatory or manufacturing processes.
- Private-market uptake may be limited by pricing, awareness, or competition from other dengue vaccines.
- No upfront payment means financial benefit is entirely dependent on future sales.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000657 |
| Document: 0001575872-26-000657-index.html | 0001575872-26-000657 |
| Document: 0001575872-26-000657.txt | 0001575872-26-000657 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $13.75 | awaiting T+5 | awaiting T+5 | $13.75 (0.00%) |
Oct 26, 2026 1d ago | 6-K | $13.75 | awaiting T+5 | awaiting T+5 | $13.75 (0.00%) |
Oct 23, 2026 4d ago | 6-K | $13.21 | awaiting T+5 | awaiting T+5 | $13.75 (−4.09%) |
Oct 23, 2026 4d ago | 6-K | $13.21 | awaiting T+5 | awaiting T+5 | $13.75 (+4.09%) |
Oct 23, 2026 4d ago | 6-K | $13.21 | awaiting T+5 | awaiting T+5 | $13.75 (+4.09%) |
Oct 23, 2026 4d ago | 6-K | $13.21 | awaiting T+5 | awaiting T+5 | $13.75 (−4.09%) |
Oct 21, 2026 6d ago | 6-K | $13.19 | awaiting T+5 | awaiting T+5 | $13.75 (+4.25%) |
Oct 14, 2026 13d ago | 6-K | $12.75 $13.19 | ▲ +3.45% | ▲ +3.00% | $13.75 (+7.84%) |
Oct 8, 2026 19d ago | 6-K | $12.20 $12.90 | ▲ +5.74% | ▲ +6.01% | $13.75 (+12.70%) |
Oct 7, 2026 20d ago | 6-K | $12.27 $12.75 | ▲ +3.91% | ▲ +4.89% | $13.75 (+12.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers